Yunnan Baiyao stock weighs steady growth against softer Q3 profit

Published on 11/04/2026 at 02:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Yunnan Baiyao stock faces mixed signals after nine-month revenue growth and a softer third-quarter profit. Huatai Securities kept its Add rating.

Growth Holds Despite Softer Quarterly Profit

Yunnan Baiyao's first-nine-month revenue rose 5.2 percent year over year.
Third-quarter attributable profit declined 2.0 percent despite double-digit revenue growth.
Huatai Securities maintained an Add rating while lowering its target price.

Yunnan Baiyao, CNE0000008X7, Illustration mit AI erstellt.

Yunnan Baiyao reported steady business growth through the first nine months of 2026, while quarterly profitability weakened. In a report published on October 30, Huatai Securities said revenue reached CNY 32.26 billion, net profit attributable to shareholders CNY 4.82 billion and non-GAAP net profit CNY 4.63 billion for the period, up 5.2 percent, 0.9 percent and 1.8 percent year over year, respectively.

Revenue Growth Meets Margin Pressure

Third-quarter revenue rose 10.4 percent year over year to CNY 10.37 billion. Attributable net profit fell 2.0 percent to CNY 1.12 billion, while non-GAAP net profit increased 2.2 percent to CNY 1.11 billion. The figures point to continued top-line momentum but less favorable quarterly earnings conversion.

Huatai Securities said the pharmaceutical business continued to expand, while health products remained stable. It also expected traditional Chinese medicine resource revenue from overseas markets to face pressure from lower raw-material prices. Sales, general and administrative expense ratios improved in the first nine months, while research and development spending increased 24 percent to CNY 340 million.

Analyst Keeps Add Rating

Huatai Securities maintained its Add rating and lowered its target price to CNY 70.50 from CNY 74.45. The brokerage forecast attributable net profit of CNY 5.53 billion for 2026, CNY 5.99 billion for 2027 and CNY 6.41 billion for 2028. Its assessment also highlighted ongoing development of traditional Chinese medicine products, chemical drugs, biologics and radiopharmaceutical programs.

For investors, the results frame Yunnan Baiyao as a diversified healthcare company balancing resilient revenue with near-term pressure on quarterly earnings. The mix of established consumer and pharmaceutical products with longer-cycle research projects leaves execution in core businesses and new product development as the main operating focus.

Healthcare Portfolio Across China

Yunnan Baiyao is a Chinese healthcare company whose businesses cover pharmaceuticals, traditional Chinese medicine resources, health products and pharmaceutical distribution. Its product portfolio includes natural medicines, Chinese herbal products, specialty drugs, medical devices, health and daily-care products, and dietary supplements. The company is headquartered in China and combines established traditional-medicine products with newer healthcare and research activities.